Long-term follow-up of people treated with Miltenyi CAR T cell therapies
Follows people with blood cancers treated with modified immune cells over time.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Key facts
- Where
- Berlin, Cologne, Erlangen, Goettingen, Muenster, Munich, Tuebingen, and Wuerzburg, GermanySee the 9 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who were treated with a Miltenyi CAR T cell therapy in an earlier trial. It follows them over a long time to check safety and results.
- Sex
- All sexes can join.
- Earlier treatment
- Must have been treated with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months before joining.
Read by machine on 12 November 2026.
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- University Hospital Cologne AöRCologne, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Universitaetsmedizin GoettingenGoettingen, GermanyTaking people
- Universitaetsklinikum Muenster AöRMuenster, GermanyTaking people
- Westfaelische Wilhelms-Universitaet MuensterMuenster, GermanyTaking people
- Klinikum der Universitaet Muenchen AöRMunich, GermanyTaking people
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyTaking people
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Miltenyi Biomedicine GmbH
- Trial code
- NCT06508775EU 2022-501648-14-00
- Record updated
- 9 October 2026
- Original description
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.Read full original descriptionShow less
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
Inclusion: Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up; Patient has provided informed consent prior to enrollment.
Exclusion: No exclusion criteria.